STOCK TITAN

Monthly information on share capital and company voting rights

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Cellectis announced updates on its share capital and voting rights as of September 30, 2020. The total number of shares in the capital reached 42,486,133, while the total voting rights amounted to 47,940,528. Specializing in CAR-T immunotherapies, Cellectis focuses on innovative gene editing technologies to treat various cancers, including acute myeloid leukemia and multiple myeloma. The company’s mission is to provide effective UCART product candidates to address unmet medical needs in oncology.

Positive
  • Total shares in capital: 42,486,133
  • Total voting rights: 47,940,528
  • Focused on developing innovative CAR-T therapies for various cancers
Negative
  • None.

(Article 223-16 of General Regulation of the French financial markets authority)

NEW YORK, Oct. 07, 2020 (GLOBE NEWSWIRE) --

Listing market: Euronext Growth

ISIN code: FR0010425595

DateTotal number of shares
in the capital
Total number of voting rights
09/30/202042,486,13347,940,528

About Cellectis
Cellectis is developing the first of its kind allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients. As a clinical-stage biopharmaceutical company with over 20 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN®, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to target and eradicate cancer cells.

As part of its commitment to a cure, Cellectis remains dedicated to its goal of providing life-saving UCART product candidates to address unmet needs for multiple cancers including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL) and multiple myeloma (MM).

Cellectis headquarters are in Paris, France, with additional locations in New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). For more information, visit www.cellectis.com.

Follow Cellectis on social media: @cellectis, LinkedIn and YouTube.

TALEN® is a registered trademark owned by Cellectis.

For further information, please contact:

Media contacts:
Jennifer Moore, SVP, Public Relations & NY Site Head 917-580-1088, media@cellectis.com
Caitlin Kasunich, KCSA Strategic Communications, 212-896-1241, ckasunich@kcsa.com

IR contact:
Simon Harnest, VP, Corporate Strategy and Finance, 646-385-9008, simon.harnest@cellectis.com

PDF available at: http://ml.globenewswire.com/Resource/Download/f3a3de01-67b4-4acd-b59a-32077058ee2f

FAQ

What is the current share capital of Cellectis?

As of September 30, 2020, Cellectis has a total share capital of 42,486,133 shares.

How many voting rights does Cellectis have?

Cellectis has a total of 47,940,528 voting rights as of September 30, 2020.

What types of cancer does Cellectis target with its therapies?

Cellectis develops therapies targeting acute myeloid leukemia, B-cell acute lymphoblastic leukemia, and multiple myeloma.

What is Cellectis's approach to CAR-T immunotherapies?

Cellectis is pioneering an allogeneic approach for CAR-T immunotherapies, offering off-the-shelf, ready-to-use gene-edited CAR T-cells.

Cellectis S.A. American Depositary Shares

NASDAQ:CLLS

CLLS Rankings

CLLS Latest News

CLLS Stock Data

188.18M
93.36M
3.87%
14.61%
0.16%
Biotechnology
Healthcare
Link
United States of America
Paris